Amarin Corporation plc
NASDAQ:AMRNBiotechnology
+$0.29 today
- Market cap
- $232.89M
- Beta
- 0.82
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$1.62
Volume 0.09M
Average 0.07M
AMRN Other Financing Activities
Financing cash flows not reported separately.
Amarin Corporation plcNASDAQ: AMRN
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities grows, but more slowly than its trailing trend
Q1 FY2026 other financing activities of $1.69M (cash outflow) rose 50.8% year over year, behind the +117.1% change in trailing-twelve-month other financing activities. Sequentially, it rose 1895.0% from the prior quarter. Over 3 fiscal years it compounded at +27.8% a year.
Context
- Other financing activities amounted to 1.0% of revenue in FY2025, up 0.3 pp from a year earlier.
- Other financing activities grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +50.8% toward the trailing-twelve-month pace of +117.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (2.18M) USD
- Year-over-year change
- -38.4%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.18M) | -38.4% |
| FY2024 | 2024-12-31 | (1.57M) | +20.9% |
| FY2023 | 2023-12-31 | (1.99M) | -90.7% |
| FY2022 | 2022-12-31 | (1.04M) | +89.2% |
| FY2021 | 2021-12-31 | (9.64M) | — |
Other Financing Activities vs competitors
How AMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +117.1% is the 2nd highest of 8, against a peer median of +95.6%.
- Other financing activities amounts to 1.3% of revenue for AMRN, versus a peer median of 3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.49M USD | +95.6% | — | 9.5% | |
| LTM Mar 2026 | $2.73M USD | +117.1% | +27.8% | 1.3% | |
| LTM Mar 2026 | $717K USD | +38.7% | — | 1991.7% | |
| LTM Mar 2026 | $229K USD | +141.9% | — | — | |
| LTM Mar 2026 | $2K USD | -300.0% | -87.1% | 6.5% | |
| LTM Dec 2025 | CHF 1.03K CHF | +100.2% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | -100.0% | — | — | |
| LTM Mar 2026 | $0 USD | — | +249.6% | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $0 USD | +100.0% | — | — |
| Peer median (excluding AMRN) | — | +95.6% | +81.3% | 3.2% | |
Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.73M | (105.74M) | (59.34M) | (82.18M) | (38.8M) |
| Depreciation & Amortization | 2.86M | 3.09M | 2.98M | 3.01M | 3.03M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 17.71M | 13.94M |
| Change in Working Capital | (115.98M) | (104.01M) | 51.27M | 36.17M | 32.28M |
| Accounts Receivables | (8.34M) | 32.98M | (2.33M) | 11.22M | (3.83M) |
| Inventory | (167.05M) | (36.4M) | 56.34M | 105.44M | 34.96M |
| Accounts Payables | 51.51M | (102.67M) | (164.64K) | (77.02M) | 14.54M |
| Other Working Capital | 7.9M | 2.07M | (2.56M) | (3.5M) | (13.39M) |
| Other Non-Cash Items | 38.86M | 26.67M | 12M | (5.73M) | (3.71M) |
| Operating Cash Flow | (66.53M) | (179.98M) | 6.91M | (31.03M) | 6.74M |
| Capital Expenditures | 2 | (2) | (24.1K) | 2 | 0 |
| Acquisitions (Net) | 4K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (290.16M) | (81.58M) | (215.93M) | (278.78M) | (200.94M) |
| Sales of Investments | 394.25M | 257.36M | 190.84M | 232.8M | 209.79M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 104.09M | 175.18M | (25.62M) | (45.98M) | 8.85M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 4.57M | 664.59K | 2.22M | 131.06K | 140.33K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.64M) | (1.04M) | (1.99M) | (1.57M) | (2.18M) |
| Financing Cash Flow | (5.07M) | (378.77K) | 230.89K | (1.44M) | (2.04M) |
| Effect of Forex Changes | 3.87K | (3.2K) | 71.37K | 33.01K | (31.6K) |
| Net Change in Cash | 32.49M | (5.18M) | (18.41M) | (78.44M) | 13.52M |
| Free Cash Flow | (66.53M) | (179.98M) | 6.88M | (31.02M) | 6.74M |
Amarin Corporation plc
NASDAQ:AMRN
Intrinsic Alpha fair value
Locked
Current Price
$11.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.